Alvotech (ALVO) Form 6-K — Aug 21, 2026
Alvotech announced on August 21, 2026 a strategic licensing and commercialization agreement with Taiwan's Lotus Pharmaceutical covering two of its pipeline candidates: AVT34, a proposed biosimilar to Imfinzi (durvalumab), and AVT87, a proposed biosimilar to Hemlibra (emicizumab), in the United States and selected Asian markets. Under the semi-exclusive U.S. structure, Alvotech retains the right to commercialize both products directly alongside Lotus, which will sell through its U.S.-based subsidiary Alvogen, while Alvotech remains the exclusive supplier for all markets and Lotus takes exclusive rights in eight Asian markets including South Korea, Taiwan, and Singapore.
Key figures
- Deal Value Usd
- up to approximately $150 million in upfront and milestone payments
- Alvotech role
- exclusive supplier for all markets; responsible for U.S. development and marketing authorizations
- Us agreement structure
- semi-exclusive — Alvotech commercializes directly alongside Lotus (via Alvogen)
- Imfinzi 2025 global sales
- $6.1 billion
- Hemlibra 2025 global sales
- CHF4.8 billion (approximately $5.8 billion)
- Asian markets granted to lotus
- 8
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.